A sensitive and specific electrospray ionization high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS-MS) method has been developed for the quantitative determination of alprazolam (AL) and oc-hydroxyalprazolam (OH-AL) in plasma. After the addition of deuterium labeled internal standards of AL and OH-AL, plasma samples were buffered to alkaline pH and extracted with toluene/methylene chloride (7:3). Dried extract residues were reconstituted in HPLC mobile phase and injected onto a reversedphase C18 HPLC column. The analytes were eluted isocratically at a flow rate of 250 pL/min using a solvent composed of methanol and water (60:40) containing 0.1% formic acid. The analyses were performed using selected reaction monitoring. The assay was sensitive to 0.05 ng/mL for both the parent drug and metabolite and linear to 50 ng/mL. The intra-assay percent coefficients of variation (%CV) for AL at 2, 5, and 20 ng/mL were all < 5.6. At these concentrations, and all OH-AL intra-assay %CVs were _< 8.4. The interassay variabilities for AL were 11.8%CV, 8.7%CV, and 8.7%CV at 2.0, 5.0, and 20.0 rig/rot, respectively. The OH-AL interassay variabilities were 9.6%CV, 9.2%CV, and 7.8%CV at the same concentrations, respectively. The assay accuracy was less than or equal to • 6.6% for both analytes at the three concentrations. The method was used to quantitate AL and OH-AL in plasma samples collected from 10 subjects who were administered a l-rag oral dose of AL. The mean AL concentration peaked at 11.5 ng/mL 1 h after the dose and AL was detectable for 48 h. The mean OH-AL concentration peaked at 0.18 ng/mL 4 h after the dose and was undelectable by 36 h. Hydrolysis of the plasma samples had little effect on the detected AL concentrations but increased OH-AL concdntrations substantially. Plasma/blood ratios for AL and OH-AL exceeded I in the study samples.
Introduction
At least 2000 different benzodiazepines (BZPs) have been synthesized (1, 2) . They are among the most widely prescribed drugs *Author to whom correspondence should be addressed.
and are used in the treatment of stress, anxiety-induced depression, panic disorders, sleep disorders, muscle spasms, alcohol withdrawal, and seizures (1, 2) . Because numerous BZPs are available and they are very popular therapeutic agents, they are frequently detected by clinical, medical examiner, drugs-anddriving, and workplace drug-testing laboratories.
Commercially available radioimmmunoassy, enzyme immunoassay, and fluorescence polarization immunoassay methods have been developed to detect various BZPs and their metabolites in urine (3) (4) (5) . These immunoassay methods have also been modified and used to test serum and blood specimens for BZPs (3, 6) . Although immunoassays can be effective screening techniques to detect some BZPs, they are primarily designed to detect metabolites of diazepam, they are not quantitative, and they lack sufficient sensitivity to detect a number of the currently available BZPs in biological samples other than urine. Numerous gas chromatographic (GC) methods have been reported for the analysis of BZPs (7) (8) (9) (10) . Although nitrogenphosphorus detectors (NPD) have been used for the analysis of BZPs (9) because BZPs contain halogens in their structures, improved sensitivity and specificity has been reported using electron-capture detection (ECD) because of their halogen-containing structures (7, 8, 10) . GC-ECD methods have been used to screen and to quantitate BZPs and their metabolites in a variety of biological samples. A sensitivity of 5 ng/mL was reported for alprazolarn (AL) (10) . Currently, capillary GC with mass spectrometry (MS) detection is the method of choice for most toxicological analyses (11) (12) (13) (14) . Electron-ionization (EI) GC-MS provides a reliable and selective analytical technique suitable for analyzing BZPs in selected biological matrices (11) (12) (13) (14) . However, several authors have demonstrated that negative-ion chemicalionization (NCI) GC-MS is more selective and sensitive than conventional EI for the analysis of BZPs (15) (16) (17) (18) . These methods recommend extraction of the BZPs with solid-phase extraction cartridges or an organic solvents and derivatization of the polar BZP metabolites. Sensitivities as low as 0.5 ng/mL for triazolam and 0.25 ng/mL for AL and et-hydroxyalprazolam (OH-AL) have been reported (17, 18) .
A disadvantage of GC methods is that most BZPs and their polar metabolites require derivatization prior to analysis. Analytes such as nordiazepam, oxazepam, hydroxytriazolam, and OH-AL all need to be derivatized to obtain Gaussian GC peaks. However, these polar compounds can be readily analyzed by high-performance liquid chromatography (HPLC) without derivatization (19) (20) (21) (22) (23) reported an HPLC-MS-MS method capable of quantitating 2 ng/mL of 1,4-benzodiazepines from serum and urine. Reported here is a HPLC-MS-MS method using positive ion electrospray ionization (ESI) capable of detecting and accurately quantitating 0.05 ng/mL of AL and OH-AL (Figure 1 ) in plasma. The method was used to measure AL and OH-AL in human plasma samples collected from a clinical study.
Experimental Reagents
High-purity-grade toluene, methylene chloride, and methanol were obtained from Baxter Diagnostics (McGaw Park, IL). Analytical-grade sodium borate was obtained from Mallinckrodt (St. Louis, MO), and concentrated formic acid was purchased from J.T. Baker (Phillipsburg, NJ). A Milli-Q | Plus water-purification system was used to obtain l~e I reagent-grade water for the HPLC solvent (Miilipore Corp., Bedford, MA). Methanolic reference solutions of AL (1.0 mg/mL), OH-AL (0.1 mg/mL), AL-ds (0.1 mg/mL), and OH-AL-ds (0.1 mg/mL) were obtained from Radian Corp. (Austin, TX).
Alprazolam

ESI HPLC-MS--MS analysis
The analyses were performed with a Finnigan-MAT | TSQ-7000 triple-stage quadrupole MS using ICIS TM OH-AL to their respective deuterium-labeled internal standards were calculated, and the concentration of each analyte in subject samples was determined from least-squares equations generated from peak-area ratios of the calibrators.
Calibrator and control preparation
Reference solutions of AL and OH-AL were combined and diluted with methanol to obtain stock solutions containing 1.0 ng/pL, 0.10 ng/pL, 0.01 ng/pL, and 0.001 ng/pL. Calibrators at each concentration were prepared in 1 mL of verified drug-free plasma by fortifying the plasma with the appropriate volume of stock solution that resulted in a calibration curve with the following concentrations of both AL and OH-AL: 0.0, 0.05, 0.10, 0.25, 0.50, 1.0, 2.5, 5.0, 10.0, 25.0, and 50.0 ng/mL. A similar dilution procedure was used to make separate stock solutions containing 1.0 ng/IJL and 0.10 ng/IJL of AL and OH-AL. These solutions were used to prepare quality-control (QC) samples.
Batches of QC samples were prepared in plasma at 2.0, 5.0 and 20.0 ng/mL, aliquoted in 1.0 mL vol- umes, and stored at-20~ until use. Concentrated internal standard solutions were combined and diluted in methanol to achieve a final concentration of 0.1 ng/pL of AL-d5 and OH-AL-ds.
Extraction
The extraction procedure was a modification of that published by H~ld et al. (18) . One milliliter of each subject sample, calibrator, or QC sample was pipetted into separate, appropriately labeled silanized 16 x 100-ram glass extraction tubes. /x^J
rain
,_~ Fifty microliters of the dilute internal standard solution (5 ng of AL-ds and OH-AL-ds) was added to each tube. The tubes were vortex mixed and allowed to equilibrate for at least 30 rain. One milliliter of saturated sodium borate buffer (pH ~ 9) was added to each tube. The tubes were mixed, and 7 mL of toluene/methylene chloride (7:3) was added. The tubes were capped, placed on a mechanical rocker for 30 min. and centrifuged for at least 10 min at > 2500 rpm. The organic solvent layer from each tube was transferred to a clean and prelabeled silanized glass 13 • 100-ram tube. The solvent was evaporated at < 40~ under a stream of air. Residues were reconstituted in 80 pL of HPLC solvent and centrifuged; the liquid was transferred into individually labeled autosampler vials.
Extraction efficiency
The extraction efficiency for AL and OH-AL was experimentally determined at 1.0, 10.0, and 50.0 ng/mL as described previously (24) . Two sets (Set A and Set B) of samples (n = 10) were prepared for the experiment. Samples in Set A contained AL and OH-AL at the stated concentrations and were extracted as discussed. Samples in Set B were extracted as described, except appropriate concentrations of AL and OH-AL were added to the extraction solvent just prior to evaporation. The ratio of analyte area to its corresponding internal standard area was obtained for each sample and the mean ratios for AL and OH-AL were calculated for samples in Sets A and B at each of the concentrations. The mean ratio at each of the three tested concentrations for Set A was divided by the mean ratio for the corresponding concentration in Set B to obtain the recovery ratio. The recovery ratio was multiplied by 100 to calculate the extraction efficiency.
Clinical study
Five healthy male and five healthy female paid volunteers were recruited. Prior to entering the study, informed consent was obtained from each subject. All subjects were given physicals, and female subjects were required to have a negative pregnancy test. Subjects entered the Clinical Research Center at the University of Utah the evening before the study. Upon admission, a urine specimen was collected and tested for AL and drugs of abuse. After an overnight fast, each subject received a 1-mg oral dose of AL. Blood samples were obtained from an anticubital vein at 0 (before dose), 0.25, 0.5, 1, 2, 4, 6, 8, 10, 12, 24, 36, and 48 h after drug administration. Blood was drawn by standard methods using separate venipunctures or an indwelling venous catheter. A portion of the sample was transferred to (or collected in) a gray-stoppered tube containing sodium fluoride and potassium oxalate, centrifuged, and the plasma retained for analysis. A second portion of whole blood was also retained. Urine and hair samples were also collected, but they are not the subject 
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of this report. Figure 3A shows a chromatogram of an extracted negative calibrator. Figure 3B shows a chromatogram of an extracted 0.05-ng/mL calibrator, and Figure 3C shows a subject's extracted plasma sample that contained 6.25 ng/mL of AL and 0.06 ng/mL of OH-AL. As shown, the retention times of AL and OH-AL were approximately 3.0 and 3.7 min, respectively. The total HPLC-MS-MS analysis time was less than 5 rain per sample. Table I shows that the calculated extraction efficiencies for AL at 1, 10, and 50 ng/mL were 88%, 99%, and 85%, respectively. Table I also shows that the extraction efficiency for OH-At at the same concentrations 102%, 85%, and 78%. The data show a tendency toward reduced extraction efficiency with increased drug and metabolite concentration. However, these data are similar to those reported by H61d et al. (18) using a similar extraction procedure. They reported that the extraction efficiency of AL from plasma approached 100% and that of OH-At was only slightly lower. 
Results
Intermay
Accuracy and precision
The accuracy and precision of the assay for AL and OH-At were experimentally determined at 2.0, 5.0, and 20.0 ng/mL using the prepared QC samples. These data are presented in Table I . For the intra-assay precision and the accuracy determinations, five replicate analyses were performed at each of the three studied concentrations. For interassay determination, samples were analyzed in duplicate in at least seven batches processed on separate days over a five-month period. The mean, standard deviation, and percent coefficient of variation (%CV) were calculated at each concentration for AL and OH-At The intra-assay %CVs for AL are all _< 5.6. All At-OH intra-assay %CVs were _< 8. 
Sample and extract stability
Samples can be processed in large batches using automated analytical procedures such as those described here. This may expose samples and their extracted residues to ambient environmental conditions for extended periods of time and potentially affect the stability of the analytes. A previous assessment of the extraction procedure demonstrated no appreciable decrease in the AL or OH-AL concentrations in samples analyzed after storage at room temperature for 0, 3, 6, and 24 h (18) . That report also demonstrated that AL and OH-AL were stable through two complete freeze-thaw cycles. To ensure that reconstituted sample residues were stable when left at room temperature inthe autosampler tray for extended periods, an additional stability experiment was performed. Calibrators, QC samples, and donor samples (n = 51) were analyzed on day 1. These same samples were all re-injected on the following day and quantitated using the calibration curve from the initial analysis. Figure 4 shows the results of this experiment. The correlation coefficient between day 1 and day 2 quantitations were 0.999 and 0.998 for AL and OH-AL, respectively.
Subject data and application of the method
The mean concentrations of AL and OH-AL from the 10 clinical subjects are shown in Figure 5 . AL was detectable within 0.25 h of administration in all subjects. The mean peak AL concentration of 11,500 pg/mL was reached at 1 h postdose, and AL was detectable at a mean concentration of 1014 pg/mL at 48 h after administration. OH-AL concentrations were less remarkable. A peak concentration of 180 pg/mL was reached at 4 h after dosing. The mean OH-AL concentrations was 55 pg/mL at 24 h and fell below the 50 pg/mL cutoff by the 36-h collection.
Discussion
ESI HPLC-MS-MS has several advantages for the analysis of BZPs and specifically, AL and OH-AL. ESI is a "gentle" ionization technique often resulting in MH § ions of small molecular weight basic drugs. Because minimal fragmentation of the analyte occurs and high mass-to-charge ratio MH + ions are produced, chemical noise is reduced and less background is observed. Because much of the total ion current is represented in the MH § ion, the signal-to-noise ratio is enhanced. MS-MS is more selective than MS. As discussed, SRM allows one to detect and quantitate the drug of interest based on preselected precursor and product ions. This technique minimizes the potential for interferences and increases the signal-to-noise ratio by focusing the detector on a particular reaction product. Figure 2 shows that there was more MS-MS fragmentation of OH-AL than AL with rn/z 205 approximately equal to that ofm/z 216. This resulted in less sensitivity for OH-AL as demonstrated in Figure 3B , where the signal-to-noise ratio of OH-AL is less than that for AL. This sensitivity could have been improved by using multiple reaction monitoring and recording the transition of m/z 325 to both 216 and 205. However, the sensitivity that was achieved for OH-AL using simple SRM was approximately 5 to 10 times greater than previously reported, and it allowed us to quantitate OH-AL following a single dose, which was previously reported as undetectable (18, 23) .
An additional advantage of HPLC-MS-MS is that no derivatization is needed even for the analysis of most polar drugs and metabolites. This eliminates the need to purchase, store and handle hazardous derivatizing reagents and simplifies sample preparation procedures. Because GC analyses require lengthy temperature programs, HPLC-MS-MS analyses are often less time consuming. This is demonstrated by the chromatograms shown in Figure 3 . Using the isocratic HPLC conditions described, the total analysis times were < 5 min per sample. A comparable GC analysis would require a temperature cycle time of approximately 10-12 rain.
Regression analysis of the calibration curves demonstrated linearity from 0.05 to 50 ng/mL for AL and OH-AL and typically gave correlation coefficients of > 0.990. These values indicated a linear relationship between the peak-area ratio and the concentration of each analyte up to 50 ng/mL. However, this form of statistical analysis tends to weight residuals from the higher concentration test points. To improve precision at the lower concentrations, a weighted 1/x or 1/x 2 model was evaluated. Using this model, precision was improved for 2.0 ng/mL and 5 ng/mL interassay precision (Table I) . At 2.0 ng/mL AL variability was reduced from 11.8%CV to 7.53%CV and the OH-AL was reduced from 9.6%CV to 8.4%CV. At 5.0 ng/mL, the AL variability was reduced from 8.7%CV to 4.7%CV and the OH-AL was reduced from 9.2%CV to 8.7%CV. Although this algorithm improved the precision at lower concentrations, it sacrificed precision at higher concentrations. Therefore, the linear model was used to quantitate AL and OH-AL in the subject samples.
BZPs are important in toxicological investigations because they are frequently prescribed and their use may adversely affect performance in complex tasks such as driving a motor vehicle (25) . Bums and Moskowitz (26) showed that a 5-rag dose of diazepam was essentially equivalent to a 0.06% blood ethanol concentration in adversely affecting pursuit-tracking, divided-attention, and information-processing tasks. Bond et al. (25) reported that AL alone or in combination with alcohol caused sedation, unsteadiness, dizziness, and impaired performance. A significant problem facing toxicologists is how to detect and quantitate short-acting BZPs such as AL and OH-AL that are in very low concentrations in biological samples such as plasma and blood. Previous studies have demonstrated that peak plasma concentrations following oral or sublingual AL administration were approximately 10 to 20 ng/mL/mg administered (27, 28) . A second study confirmed this finding estimating that the steady-state plasma concentration averaged 11.7 ng/mL/mg/day (29) . Single 1-mg doses produced peak plasma concentrations of 12 to 22 ng/mL (27, 28) . Figure 5 shows that our data are consistent with these data. Following the single acute dose, the mean peak concentration of 11.5 ng/mL was reached at 1 h postdose. Reports have also shown that OH-AL is active and that it is present in the plasma are approximately 10 to 15% of the parent AL concentration (27, 29) . The challenge of detecting and quantitating AL and OH-AL is compounded because AL is about 70% bound to plasma proteins and OH-AL is principally conjugated in urine (27) . To assess the effect of hydrolysis on AL and OH-AL plasma concentrations, plasma samples were incubated with 5000 ILl of [3-glucuronidase at 37~ overnight. The ratio of nonhydrolyzed to hydrolyzed AL concentrations was 0.87, demonstrating little effect from the hydrolysis. Hydrolysis had a dramatic effect on the OH-AL concentrations. The ratio of nonhydrolyzed to hydrolyzed OH-AL concentrations was 0.13. Therefore, the detectability of OH-AL can be improved by hydrolysis of the rnetabolite.
Most forensic laboratories receive whole blood for testing, and very little literature addresses the differences between plasma and whole blood drug concentrations even though differences due to soluability and plasma-protein binding have been demonstrated for some drugs (30) . To determine the plasma/blood ratio for At, and OH-AL, the whole blood samples from the clinical study were analyzed. It was not necessary to modify the extraction, chromatographic, or MS conditions for the analysis of the whole blood samples. The plasma/blood ratios for AL and OH-AL were 1.25 and 1.43, respectively. These findings demonstrate the potential liabilities of predicting effects and drug dose from body fluid drug concentrations. These findings should be considered when attempting to predict drug effects because most studies comparing performance and physiological responses to drug concentration are based on plasma results. Predicting driving performance from a blood AL concentration without correcting for the plasma/blood ratio might underestimate the potential drug effects. The plasma/blood ratios should also be considered when attempting to estimate AL dose from a blood drug concentration. The estimates of dose from a blood concentration would likely underestimate the dose of AL consumed if compared with the plasma pharmacokinetic literature.
Conclusions
Presented has been an ESI HPLC-MS--MS SRM method for the analysis of AL and OH-AL using an isocratic solvent system at a flow of 250 pL/min. A one-step liquid-liquid extraction method was used to extract both AL and OH-AL from plasma, and no derivatization of the analytes was required to obtain acceptable chromatography. Extraction efficiencies exceeded 78%, and the presented method was precise and accurate. The intra-assay %CVs for AL at 2, 5, and 20 ng/mL were all < 5.6. At these concentrations, all OH-AL intra-assay %CVs were < 8.4. The interassay variabilities for AL were 11.8 %CV, 8.7%CV, and 8.7%CV at 2.0, 5.0, and 20.0 ng/mL, respectively, and the OH-AL interassay variabilities were 9.6%CV, 9.2%CV, and 7.8%CV at the same concentrations. All accuracy-test challenges were within • 6.6% of their expected concentrations. The method had a routine sensitivity of 0.05 ng/mL for both the parent drug and metabolite and was linear to 50 ng/mL. The ESI HPLC--MS-MS method for the analysis of AL and OH-AL in biological samples had several advantages, including improved sensitivity, no required derivatization, and reduced analysis times, compared with conventional GC-MS methods, over previously published methods. The sensitivity of the assay was sufficient to detect and
